Why Is TWIST BIOSCIENCE COR (TWST) Stock Up Today?

Twist Bioscience (NASDAQ:TWST) shares surged 9.30% to $100.06 in early trading on August 4, 2026, following the release of its fiscal 2026 third-quarter results. The company reported revenue of $118.4 million, a 23% year-over-year increase, and raised its full-year revenue guidance. Despite a GAAP EPS of -$0.56, which missed estimates by $0.08, the strong revenue performance and updated guidance contributed to the sharp intraday rebound.

What Happened

The stock opened at $89.51, a 2.2% gap down from the prior close, but quickly reversed course. The session low of $80.59 at the market open was followed by a steady climb, with the stock reaching a high of $100.62 at 11:30 AM ET. Investors responded positively to the company's 14th consecutive quarter of revenue growth and the upward revision of its full-year revenue forecast to a range of $456 million to $457 million. The updated Q4 sales guidance of $123 million to $124 million also signaled continued momentum in the company's core business. These developments came after recent negative sentiment driven by a mixed earnings report and a focus on the company's ongoing unprofitability.

What The Data Shows

The stock traded at a volume of 1.0 million shares, which is 0.6 times the 3-month daily average. The intraday move reflects a sharp recovery from a recent price decline, as the stock had fallen to $91.59 over the previous 8 sessions. The 52-week range is $23.30 to $105.47, with the current price near the upper end. The company has a market cap of $5.7 billion, with trailing twelve-month earnings per share of -1.34 and a net margin of -19.8%. Over the last 90 days, insiders have sold shares totaling $13.9 million, with the most recent transaction reported on July 27.

What To Watch

Twist Bioscience has not scheduled an earnings date for the current quarter. Investors should monitor the breadth of analyst coverage and any further updates on the company's financial guidance or R&D progress.